Treating serious infections: Focus on cefepime

Pharmacotherapy

Volumn 24, Issue 12 II, 2004, Pages

  Wong Beringer, Annie ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Antibiotic resistance; Broad spectrum antibiotics; Cefepime; Febrile neutropenia; Nosocomial infections; Pneumonia

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL VIRULENCE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DRUG INDICATION; DRUG RESPONSE; DRUG SURVEILLANCE PROGRAM; ENTEROBACTER; ENTEROCOCCUS; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; HOSPITAL INFECTION; HUMAN; INFECTION SENSITIVITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMONIA; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

CEPHALOSPORINS; CROSS INFECTION; HUMANS; NEUTROPENIA; PNEUMONIA, BACTERIAL;

EID: 9644289375     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.18.216S.52237     Document Type: Conference Paper

References (31)

1. Eggimann P, Pittet D. Infection control in the ICU. Chest 2001;120:2059-93.
2. Centers for Disease Control and Prevention. Public health focus: surveillance, prevention, and control of nosocomial infections. MMWR Morb Mortal Wkly Rep 1992;41:783-7.
3. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000;31(suppl 4):S131-8.
4. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999;27:520-32.
5. Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 2001;119:397S-404.
6. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992-June 2003, issued August 2003. Am J Infect Control 2003;31:481-98.
7. Centers for Disease Control and Prevention. Slide presentation: campaign to prevent antimicrobial resistance, slides 9 and 10. Available from http://www.cdc.gov/drugresistance/healthcare/ha/Haslideset_clean.ppt. Accessed June 22, 2004.
8. Wong-Beringer A. Therapeutic challenges associated with extended-spectrum, β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Pharmacotherapy 2001;21:583-92.
9. Hsu DI, Wong-Beringer A, Okamoto M. Ciprofloxacin-resistant Pseudomonas aeruginosa: risk factors for acquisition and associated outcomes. Presented at the 41st annual meeting of the Infectious Diseases Society of America, San Diego, CA, October 9-12, 2003.
10. Centers for Disease Control and Prevention. Pneumonia fastats. Available from http://www.cdc.gov/nchs/fastats/pneumonia.htm. Accessed August 18, 2004.
11. Konstantinou K, Baddam K, Lanka A, Reddy K, Zervos M. Cefepime versus ceftazidime for treatment of pneumonia. J Int Med Res 2004;32:84-93.
12. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2001;32:S81-93.
13. Jones RN, Varnam DJ. Antimicrobial activity of broad-spectrum agents tested against gram-negative bacilli resistant to ceftazidime: report from the SENTRY antimicrobial surveillance program (North America, 2001). Diag Microbiol Infect Dis 2002;44:379-82.
14. Kuderer NM, Crawford J, Dale DC, Lyman GH, for the Absolute Neutrophil Count Study Group. Complications and costs associated with febrile neutropenia in hospitalized adult cancer patients. Presented at the annual meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004.
15. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
16. Klastersky JA, ed. Febrile neutropenia. Berlin: Springer-Verlag Telos, 1997:47-52.
17. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-74.
18. Ibrahim EH, Ward S, Sherman G, Kollef MH. A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting. Chest 2000;117:1434-42.
19. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998;244:379-86.
20. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997;111:676-85.
21. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit: ICU-acquired pneumonia study group. Intensive Care Med 1996;22:387-94.
22. Rello J, Gallego M, Mariscal D, et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997;156:196-200.
23. Kollef MH, Ward S, Sherman G, et al. Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices. Crit Care Med 2000;28:3456-64.
24. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998;157:531-9.
25. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115:585-90.
26. Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003;9:1415-22.
27. Elan Pharmaceuticals. Maxipime (cefepime HCl) prescribing information. San Diego, CA; 2003.
28. Mutnik AH, Rhomberg PR, Sader HS, Jones RN. Antimicrobial usage and resistance trend relationships from the MYSTIC programme in North America (1999-2001). J Antimicrob Chemother 2004;53:290-6.
29. Ambrose PG, Richerson MA, Stanton ME, et al. Cost-effectiveness analysis of cefepime compared with ceftazidime in intensive care unit patients with hospital-acquired pneumonia. Infect Dis Clin Pract 1999;8:245-51.
30. Raad II, Escalante C, Hachem RY, et al. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer 2003;98:1039-47.
31. Owens RC, Owens CA, Holloway WJ. Reduction in vancomycin consumption in patients with fever and neutropenia. Presented at the 38th annual meeting of the Infectious Diseases Society, New Orleans, LA, September 7-10, 2000.